NASDAQ:HURA

TuHURA Biosciences Q3 2025 Earnings Results & Report

TuHURA Biosciences logo
$1.41 +0.01 (+0.71%)
As of 01:26 PM Eastern
This is a fair market value price provided by Massive. Learn more.

TuHURA Biosciences beat analyst earnings expectations in its Q3 2025 results, released November 14, 2025. The company reported EPS of -$0.14 versus the -$0.15 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call
7:00 AM ET

TuHURA Biosciences EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.15
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

TuHURA Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

TuHURA Biosciences Q3 2025 Earnings FAQ

TuHURA Biosciences (NASDAQ:HURA) reported earnings of -$0.14 per share for Q3 2025, beating the consensus estimate of -$0.15. The report was announced on Friday, November 14, 2025.

TuHURA Biosciences Earnings Headlines

Your $7 scanner is waiting
The Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.tc pixel
See More TuHURA Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TuHURA Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TuHURA Biosciences and other key companies, straight to your email.

About TuHURA Biosciences

TuHURA Biosciences (NASDAQ:HURA) is a clinical-stage biotechnology company developing immunotherapies for cancer. Its research focuses on treatments intended to stimulate the immune system and address mechanisms that allow tumors to evade immune attack.

The company’s pipeline includes IFx-2.0, an investigational intratumoral immunotherapy being studied for use with checkpoint inhibitors, as well as antibody programs targeting immune-regulating pathways. TuHURA has no marketed products, and its candidates remain in development.

TuHURA became a publicly traded company following its 2024 merger with Kintara Therapeutics. The company is based in Tampa, Florida, and is led by President and Chief Executive Officer James Bianco.

View TuHURA Biosciences Profile